MEN1 and neoplasm: MEN1-related aggressive tumours or other malignancies were more frequent in participants with the CDKN1B genetic variant (8/24 patients in group A versus 5/31 in group B; 33.3 versus 16.1%), although this test did not result in statistical significance (P = NS) (Table3).